Company news

Esperion Therapeutics, Inc. news in 2021

Esperion Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Esperion Announces Closing of $225 Million Public Offering

December 6, 2021

Esperion Announces Proposed Public Offering

December 1, 2021

Esperion Announces Pricing of $225 Million Public Offering

December 1, 2021

Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update

November 1, 2021

Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors

October 31, 2021

ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock

October 24, 2021

ESPERION Announces Plan for Transformative Long-Term Growth

October 17, 2021

Esperion to Report Third Quarter 2021 Financial Results November 2, 2021

October 11, 2021

ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update

August 2, 2021

Esperion to Report Second Quarter 2021 Financial Results August 3, 2021

July 12, 2021

ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer

June 27, 2021

ESPERION Appoints Sheldon Koenig as President and CEO

May 16, 2021

ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update

May 3, 2021

Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal

April 26, 2021

Esperion to Report First Quarter 2021 Financial Results May 4, 2021

April 11, 2021

ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

February 22, 2021

Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021

February 8, 2021

ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program

January 12, 2021

Calls in 2021